Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 6/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 3/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13419201 | 0.92 | FAAH (0.48) | MTTPHCRTR1HCRTR2FAAHUBE2M | |
| SCHEMBL13419184 | 0.92 | MTTP (0.53) | MTTPHCRTR1HCRTR2FAAHUBE2M | |
| SCHEMBL13419155 | 0.92 | MTTP (0.47) | MTTPHCRTR1HCRTR2FAAHUBE2M | |
| SCHEMBL13419545 | 0.91 | MTTP (0.51) | MTTPHCRTR1HCRTR2FAAHUBE2M | |
| SCHEMBL5796728 | 0.91 | MTTP (0.54) | MTTPHCRTR1HCRTR2FAAHUBE2M | |
| SCHEMBL13419205 | 0.91 | MTTP (0.54) | MTTPHCRTR1HCRTR2FAAHUBE2M | |
| SCHEMBL13419140 | 0.90 | MTTP (0.47) | MTTPHCRTR1HCRTR2FAAHPTGER1 | |
| SCHEMBL13419152 | 0.89 | SCD5 (0.50) | MTTPHCRTR1HCRTR2FAAH | |
| SCHEMBL13419198 | 0.89 | HCRTR1 (0.47) | MTTPHCRTR1HCRTR2FAAHTSHR | |
| SCHEMBL13419471 | 0.89 | MTTP (0.47) | MTTPHCRTR1HCRTR2FAAHUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674803-B2 | Thiazolypiperidine derivatives as MTP inhibitors | MERCK PATENT GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7674803-B2 | Thiazolypiperidine derivatives as MTP inhibitors | MERCK PATENT GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| EP-1636218-B1 | THIAZOLYLPIPERIDINE DERIVATIVES AS MTP INHIBITORS | MERCK PATENT GMBH (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MERCK PATNET GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054939-A1 | Thiazolypiperidine derivatives as mtp inhibitors | MTTP, CETP, APOB | MTTP 1/4885HCRTR1 2448/4885HCRTR2 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.